Abstract
Optimistic versus pessimistic prognosis depends much on diagnostic, preventive and treatment approaches which healthcare will preferably adopt in the near future. Currently there are over 350 million diabetic patients frequently affected by polyneuropathy as secondary complication, 18 million patients with Alzheimer’s disease also diagnosed as Diabetes Type 3, neurodegenerative eye diseases with leading causes of blindness – diabetic retinopathy and estimated 67 million glaucoma patients worldwide, millions of patients with Parkinson’s disease, Multiple Sclerosis, Epilepsy, Cerebral Palsy and Dementia in the elderly – altogether dramatically affect life quality, social and economical indexes of populations around the globe. Without innovation in healthcare, neurodegenerative disorders can reach more than 30% of global disease burden till 2020. In contrast, effective utilisation of advanced early/predictive diagnostics, preventive and personalised medical approaches could enable a significant portion of population to reach the 100-year age limit remaining vibrant in excellent physical and mental health as actively contributing members of society.
Neurodegenerative diseases are pathologies of multifactorial nature involving interplay of epigenetic and environmental risk factors. Insights into molecular pathomechanisms will enable to create the most effective targeted protective strategies and individualised treatment before manifest pathology. Multifunctional “cocktail” therapies need to be created for individual multifactorial pathologies, in order to advance the healthcare of the patient cohorts. Particular emphasis should be placed on primary prevention: identification of predisposed individuals early in life followed by treatments tailored to the person need regulations by innovative reimbursement programmes. This strategy creates a robust platform for the cost-effective medicine of the future.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Golubnitschaja O (2010) Neurodegeneration: accelerated ageing or inadequate healthcare? EPMA J 1:211–215
Scarpa M (2011) Advanced healthcare for children and youth: application of targeted prevention, predictive diagnostics and personalised treatment approaches. EPMA J 2:137–139
Peeva V, Golubnitschaja O (2009) Birth asphyxia as the most frequent perinatal complication. In: Golubnitschaja O (ed) Predictive diagnostics and personalized treatment: dream or reality. Nova Science Publishers Inc, New York
Yeghiazaryan K, Peeva V, Morelli M, Herrera-Marshitz M, Golubnitschaja O (2009) Potential targets for early diagnosis and neuroprotection in asphyxiated newborns. In: Golubnitschaja O (ed) Predictive diagnostics and personalized treatment: dream or reality. Nova Science Publishers Inc, New York
Tounta G, Kolialexi A, Papantoniou N, Tsangaris G, Kanavakis E, Mavrou A (2011) Non-invasive prenatal diagnosis using cell-free fetal nucleic acids in maternal plasma: progress overview beyond predictive and personalized diagnosis. EPMA J 2:163–171
Tasker R, Adams-Marriott A, Shaw C (2010) New animal models of progressive neurodegeneration: tools for identifying targets in predictive diagnostics and presymptomatic treatment. EPMA J 1:217–227
Yeghiazaryan K, Flammer J, Orgül S, Wunderlich K, Golubnitschaja O (2009) Vasospastic individuals demonstrate significant similarity to glaucoma patients as revealed by gene expression profiling in circulating leukocytes. Mol Vis 15:2339–2348
Yeghiazaryan K, Flammer J, Golubnitschaja O (2010) Predictive molecular profiling in blood of healthy vasospastic individuals: clue to targeted prevention as personalised medicine to effective costs. EPMA J 1:263–272
Fulda S (2011) Idiopathic REM sleep behavior disorder as a long-term predictor of neurodegenerative disorders. EPMA J 2:451–458
Grossman I, Lutz M, Crenshaw D, Saunders A, Burns D, Roses A (2010) Alzheimer’s disease: diagnostics, prognostics and the road to prevention. EPMA J 1:293–303
Mandel S, Morelli M, Halperin I, Korczyn A (2010) Biomarkers for prediction and targeted prevention of Alzheimer’s and Parkinson’s diseases: evaluation of drug clinical efficacy. EPMA J 1:273–292
Gozes I (2010) Tau pathology: predictive diagnostics, targeted preventive and personalized medicine and application of advanced research in medical practice. EPMA J 1:305–316
Grossman I, Miller A (2010) Multiple sclerosis pharmacogenetics: personalized approach towards tailored therapeutics. EPMA J 1:317–327
Döring A, Pfueller CF, Paul F, Dörr J (2011) Exercise in multiple sclerosis – an integral component of disease management. EPMA J 3:2
Nefussy B, Drory V (2010) Moving toward a predictive and personalized clinical approach in amyotrophic lateral sclerosis: novel developments and future directions in diagnosis, genetics, pathogenesis and therapies. EPMA J 1:329–341
Benkler C, Offen D, Melamed E, Kupershmidt L, Amit T, Mandel S, Youdim M, Weinreb O (2010) Recent advances in amyotrophic lateral sclerosis research: perspectives for personalized clinical application. EPMA J 1:343–361
Lagrange F (1922) Du glaucome et de l’hypotonie; leur traitement chirurgical. Doin, Paris
Pache M, Flammer J (2006) A sick eye in a sick body? Systemic findings in patients with primary open-angle glaucoma. Surv Ophthalmol 51:179–212
Golubnitschaja O, Yeghiazaryan K, Flammer J (2010) Key molecular pathways affected by glaucoma pathology: is predictive diagnosis possible? EPMA J 1:237–244
Mozaffarieh M, Fraenkl S, Konieczka K, Flammer J (2010) Targeted preventive measures and advanced approaches in personalised treatment of glaucoma neuropathy. EPMA J 1:229–235
Hasler P, Flammer J (2010) Predictive, preventive and personalised medicine for age-related macular degeneration. EPMA J 1:245–251
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Mandel, S., Golubnitschaja, O. (2013). Time for New Guidelines in Handling of Neurodegenerative Disorders: Optimistic Versus Pessimistic Prognosis by Application of PPPM. In: Mandel, S. (eds) Neurodegenerative Diseases: Integrative PPPM Approach as the Medicine of the Future. Advances in Predictive, Preventive and Personalised Medicine, vol 2. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-5866-7_1
Download citation
DOI: https://doi.org/10.1007/978-94-007-5866-7_1
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-5865-0
Online ISBN: 978-94-007-5866-7
eBook Packages: MedicineMedicine (R0)